In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

Minimal residual disease negativity was achieved at a significantly higher rate with venetoclax-based therapies, supporting its role in CLL.

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events ...

Chronic lymphocytic leukemia-- or CLL-- is a type of cancer ... but because of the change-- called a mutation-- faulty white blood cells that don't work like they should are made instead.

The combination’s fixed-duration treatment is intended to achieve deeper remission for treatment-naïve subjects with no ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.